Answers are grounded in this paper and cite their sources.
This study aimed to assess the drug utilization of anticancer drugs in breast cancer patients at a tertiary care teaching hospital. The objectives were to identify the most commonly prescribed chemotherapeutic drugs and to study the side-effect profile using the CTCAE grading. A prospective observational study was conducted in the medical oncology department. Data was collected from 93 patients and analyzed for prescribing patterns, drug utilization, and side-effects. The majority of patients were aged 46-55 years (48.38%) and in stage III cancer (62.36%). Luminal B was the most common molecular subtype (35.48%). Neoadjuvant therapy was administered to 59.13% of patients, while 40.86% received adjuvant therapy. Trastuzumab was the most frequently prescribed drug in both neoadjuvant (34.54%) and adjuvant (36.84%) therapies. Ondansetron, aprepitant, dexamethasone, and olanzapine were commonly used as supportive treatments. Side-effects were experienced by 76.34% of patients, with 71.83% having grade 1 and 28.16% having grade 2 side-effects. The most frequent side-effects were nausea, vomiting, and alopecia. The onset of side-effects was highest after the 3rd chemotherapy cycle (28.16%). The study provides valuable information about the prescribing patterns and side-effect profile of anticancer drugs in breast cancer patients
No takes yet. Share an insight, caveat, or question.
Ellampati et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: